According to post on the FDA’s website, Agios Pharmaceuticals’ treatment of myelodysplastic syndromes was designated for orphan status.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024
- Closing Bell Movers: Airbnb, TripAdvisor down double digits on earnings
- Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib
- Agios to receive $1.1B in milestone payments after FDA approval of vorasidenib
- Agios Pharmaceuticals reports results from Phase 3 ACTIVATE-KidsT study